TABLE 5.

Frequency and risks of outcomes during the potential rebound period (16 to 24 months of age)

Outcome	Placebo group (n = 529)			SP group (n = 525)			% PE (95% CI)	P
	No. of events or cases	PYARa	Rateb	No. of events or cases	PYAR	Rate
Malaria
All episodes	553	313.1	1.77	548	308.2	1.78	−1.0 (−17.6-13.2)	0.89
First or only episode	319		0.60	311		0.59	1.8 (−8.5-11.0)	0.73
Anemia (Hb of <7 g/dl)
All episodes	220	331.4	0.66	208	327.0	0.64	3.8 (−21.1-23.6)	0.74
First or only episode	164		0.31	151		0.29	7.2 (−11.7-22.9)	0.43
Severe malaria
All episodes	13	344.3	0.04	25	338.4	0.07	−97.2 (−296.6-2.0)	0.06
First or only episode	12		0.02	24		0.05	−101.5 (−298.9 to −1.8)	0.04
Severe malarial anemia
All episodes	11	344.4	0.03	24	338.4	0.07	−124.2 (−373.0 to −6.2)	0.03
First or only episode	10		0.02	23		0.04	−131.8 (−382.3 to −11.4)	0.03
Asymptomatic parasitemia
All episodes	282	328.8	0.86	238	326.1	0.73	14.8 (−4.4-30.4)	0.12
First or only episode	208		0.39	172		0.33	16.7 (2.0-29.1)	0.03
Death	13		0.02	6		0.01	53.1 (−22.4-82.1)	0.12

^aPYAR, person-years at risk. For this calculation person-years at risk starts at 16 months of age.

^bRate designates either incidence density (number of events/person-year at risk) or risk (number of cases/children at risk).